Michael Hallek, MD from the University of Cologne, Cologne, Germany gives an overview of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) meeting, wich will be held in New York City on May 12-15, 2017. According to Prof. Hallek, combinations of new agents will be a hot topic and there will be a debate about prognostic factors in the era of novel agents. For example, the new prognostic score called CLL-IPI will be discussed in the context of novel drugs. Another topic will be the pathogenesis of CLL and how an understanding of the different pathways will provide novel targets.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.